Biochemical bone markers and bone mass study in recently postmenopausal women without osteoporosis;Marcadores bioquímicos de remodelado en el estudio de la masa ósea en la mujer con menopausia reciente sin osteoporosis

Medicina Clinica

Volumn 124, Issue 7, 2005, Pages 241-249

  Ferrer Cañabate, Jaime ^a,b   Tovar Zapata, Isabel ^a   Tortosa Oltra, Josefa ^a   Martínez Hernández, Pedro ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b HOSPITAL RAFAEL MÉNDEZ   (Spain)

Author keywords

Biochemical bone markers; Hormonal replacement therapy (HRT); Menopause; Postmenopause

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; OSTEOCALCIN;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT MONITORING; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REFERENCE VALUE;

EID: 16244387650     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13072034     Document Type: Article

References (29)

1. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporosis Int. 1998;8:468-89.
2. Melton LJ III. How many women have osteoporosis now? J Bone Miner Res. 1995;10:175-7.
3. Lydick E, Cook K, Turpin J, Melton M, Stine R, Byrnes C. Development and validation of a simple questionnaire to facilitate identification of women likely to have low bone density. Am J Manag Care. 1998;4:37-48.
4. Díaz CM, Carrasco de la Peña JL, Honorato PJ, Pérez CR, Rapado A, Ruiz MI. Study of bone mineral density in lumbar and femoral neck in a Spanish population. Multicentre Research Project on Osteoporosis. Osteoporos Int. 1997;7:59-54.
5. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, et al. Bone turnover markers and bone density across the menopause transition. J Clin Endocrinol Metab. 1996;81:3366-71.
6. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone. 1999;24:237-44.
7. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res. 1999;4:1614-21.
8. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, et al. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Bone Miner Res. 1999;14:1583-95.
9. Delmas PD, Hardy P, Garnero P, Dain M. Monitoring individual response to hormone replacement therapy with bone markers. Bone. 2000;26:553-60.
10. Lomeo A, Bolner A. Stability of several biochemical markers of bone metabolism. Clin Chem. 2000;46:1200-2.
11. Bernard M, Jaramillo G, Aguado P, Del Campo T, Coya J, Martin M, et al. Polimorfismos del gen para el receptor de la vitamina D y densidad mineral ósea en mujeres posmenopáusicas. Med Clin (Barc). 1999;112:651-5.
12. Tannebaum C, Clark J, Scwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431-7.
13. Rodríguez Espinosa J, Queralto Compano JM. Acerca del uso clínico de los nuevos marcadores bioquímicos de remodelado óseo. Med Clin (Barc). 1999;112:517-8.
14. Chaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, et al. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J Bone Miner Res. 2000;15:1537-44.
15. De la Piedra C, Traba ML, Domínguez Cabrera C, Sosa Henríquez M: New biochemical markers of bone resorption in the study of postmenopausal osteoporosis. Clin Chim Acta. 1997;265:225-34.
16. Van Daele PL, Seibel MJ, Burger H, Hofman A, Grobbee DE, Van Leeuwen JP, et al. Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study. BMJ. 1996;312:482-3.
17. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531-8.
18. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526-36.
19. Ross PD, Kress BC, Parson RE, Wasnich RD, Amour KA, Mizhari I. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporosis Int. 2000;11:76-82.
20. Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone. 1996;19:9-12.
21. Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone. 2000;27:283-6.
22. Rosen CJ, Chesnut CH III, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab. 1997;82:1904-10.
23. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab. 1991;72:367-73.
24. Johansen JS, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur J Clin Invest. 1988;18:191-5.
25. Greenspan S, Bankhurst A, Bell N, et al. Effects of alendronate and estrogen, alone or in combination, on bone mass and turnover in postmenopausal osteoporosis. Bone. 1998;23 Suppl:174.
26. Chesnut C, Bell NH, Clark GS, Drinkwater BL, English SC, Jonhston CC, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29-37.
27. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 1994;9:255-64.
28. Ferrer-Cañabate J, Egea-Mellado, JM, Martínez- Hernández P, Tovar-Zapata I. Viaje al mundo de la osteoprosis. An Med Interna. 2000;17:395-8.
29. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2003;288:321-33.